Beyond lowering LDL cholesterol

被引:5
|
作者
Bayturan, Ozgur [1 ]
Utuk, Ozan [1 ]
Tuzcu, E. Murat [2 ]
机构
[1] Celal Bayar Univ, Tip Fak, Kardiyol Anabilim Dali, Manisa, Turkey
[2] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2011年 / 11卷 / 02期
关键词
Residual risk; LDL; atherogenic dyslipidemia; apolipoprotein B; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; VERY-LOW LEVELS; PHOSPHOLIPASE A(2); CARDIOVASCULAR EVENTS; HDL CHOLESTEROL; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; APOLIPOPROTEIN-B;
D O I
10.5152/akd.2011.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Compelling evidence from randomized controlled studies demonstrated the crucial role of lowering low-density lipoprotein cholesterol (LDL-C) in the prevention of vascular events. However, not all patients with low LDL-C levels show similar reduction in event rates. The residual risk factors associated with ongoing vascular events despite achieving low LDL-C levels remain to be elucidated. New data suggest that beyond statin therapy, inflammatory mediators, high non-HDL (high-density lipoprotein) cholesterol or apolipoprotein B, small dense LDL-C, type 2 diabetes mellitus, and lifestyle features may have impact on residual vascular risk. In this review, we discussed the significance of identifying these residual risk factors and developing new treatment strategies to further decrease vascular events. The importance of imaging arterial wall to evaluate the effect of various medical therapies has also stated. (Anadolu Kardiyol Derg 2011; 11: 163-7)
引用
收藏
页码:163 / 167
页数:5
相关论文
共 50 条
  • [31] Novel LDL lowering strategies: beyond statins
    Shah, P. K.
    CARDIOLOGY, 2013, 126 : 200 - 200
  • [32] Statins: effects beyond cholesterol lowering
    Massy, ZA
    Guijarro, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (09) : 1738 - 1741
  • [33] Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
    Xiao, Changting
    Dash, Satya
    Morgantini, Cecilia
    Hegele, Robert A.
    Lewis, Gary F.
    DIABETES, 2016, 65 (07) : 1767 - 1778
  • [34] LOWERING PLASMA-CHOLESTEROL BY RAISING LDL RECEPTORS
    BROWN, MS
    GOLDSTEIN, JL
    NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (09): : 515 - 517
  • [35] Lowering LDL cholesterol in clinical practice: time for change?
    Abushamat, Layla A.
    Ballantyne, Christie M.
    LANCET, 2022, 400 (10349): : 341 - 343
  • [36] New and Emerging LDL Cholesterol-Lowering Drugs
    Kosmas, Constantine E.
    Frishman, William H.
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (03) : 234 - 241
  • [37] Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
    Haynes, Richard
    Lewis, David
    Emberson, Jonathan
    Reith, Christina
    Agodoa, Lawrence
    Cass, Alan
    Craig, Jonathan C.
    de Zeeuw, Dick
    Feldt-Rasmussen, Bo
    Fellstrom, Bengt
    Levin, Adeera
    Wheeler, David C.
    Walker, Rob
    Herrington, William G.
    Baigent, Colin
    Landray, Martin J.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 25 (08): : 1825 - 1833
  • [38] Lowering Plasma Cholesterol by Raising LDL Receptors - Revisited
    Young, Stephen G.
    Fong, Loren G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (12): : 1154 - 1155
  • [39] Is intensive LDL-cholesterol lowering beneficial and safe?
    Cheung, Bernard M. Y.
    Lam, Karen S. L.
    LANCET, 2010, 376 (9753): : 1622 - 1624
  • [40] Cognition After Lowering LDL-Cholesterol With Evolocumab
    Gencer, Baris
    Mach, Francois
    Guo, Jianping
    Im, KyungAh
    Ruzza, Andrea
    Wang, Huei
    Kurtz, Christopher E.
    Pedersen, Terje Rolf
    Keech, Anthony C.
    Ott, Brian R.
    Sabatine, Marc S.
    Giugliano, Robert P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (18) : 2283 - 2293